Antibody longevity following Plasmodium vivax infections

Antibody longevity following Plasmodium vivax infections

Project details

Renewed intensification of global malaria control efforts over the past 10 years has had significant success, however, key challenges remain, including the predominance of the species Plasmodium vivax in regions nearing elimination. Development of an effective vaccine against P. vivax would make elimination a more attainable goal. 

Our research group is addressing the challenge of P. vivax vaccine development by developing a better understanding of naturally acquired immune responses to this parasite. Our preliminary research has identified that responses to a number of key proteins of the parasite are acquired and maintained differently in countries with different transmission levels, and this project will work to further characterise such responses. This project will involve immunological techniques, data analysis, and work with international collaborators.

About our research group

The Mueller laboratory is part of the Population Health and Immunity division and currently includes eight postdoctoral fellows, two PhD students, one clinician and two research assistants based at Parkville, and an additional two postdoctoral fellows and two PhD students based overseas. Collectively, we have a wide range of expertise in immunology, molecular biology, epidemiology, statistics and modeling. 

We have a strategic network of national and international collaborators, and actively conduct field epidemiology studies with our partners in Thailand, Brazil, Papua New Guinea and the Solomon Islands. Our group's ultimate goal is to contribute to malaria elimination programs.


Rhea Longley profile
Population Health and Immunity division

Professor Ivo Mueller

Professor Ivo Mueller
Joint Division Head

Project Type: